MGLN · Magellan Health Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $7.31B | $5.84B | $4.84B | $4.60B |
| Cost of Revenue | $2.18B | $1.90B | $1.82B | - | - | - |
| Gross Profit | $143.96M | $252.67M | $227.96M | $310.89M | $301.79M | $275.65M |
| R&D | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $98.39M | $131.51M | $132.66M | $115.71M | $106.05M | $102.84M |
| Operating Income | ($40.48M) | $80.82M | $43.19M | $135.22M | $145.52M | $71.12M |
| Interest Expense | $30.86M | $36.15M | $35.40M | $25.98M | $10.19M | $6.58M |
| Income Tax | ($44.53M) | $24.91M | $19.01M | $25.08M | $69.73M | $42.41M |
| Net Income | $382.33M | $55.90M | $24.18M | $110.21M | $77.88M | $31.41M |
| EPS - Basic | $15.14 | $2.31 | $0.99 | $4.72 | $3.36 | $1.26 |
| EPS - Diluted | $14.98 | $2.28 | $0.97 | $4.51 | $3.22 | $1.21 |
Balance Sheet
| Line item | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.14B | $325.25M | $272.31M | $398.73M | $304.51M | $115.43M |
| Accounts Receivable | $743.50M | $890.07M | $756.06M | $660.77M | $606.76M | $428.64M |
| Inventory | $43.33M | $44.96M | $40.82M | $40.95M | $58.99M | $50.75M |
| Accounts Payable | $137.38M | $88.42M | $72.08M | $74.30M | $95.64M | $86.48M |
| Current Assets | $2.16B | $1.67B | $1.55B | $1.48B | $1.32B | $1.10B |
| Total Assets | $3.36B | $3.09B | $2.98B | $2.96B | $2.44B | $2.07B |
| Current Liabilities | $737.58M | $910.15M | $898.89M | $892.30M | $1.09B | $724.24M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $1.46B | $1.69B | $1.69B | $1.68B | $1.34B | $996.94M |
| Stockholders' Equity | $1.87B | $1.40B | $1.29B | $1.28B | $1.10B | $1.07B |
| Retained Earnings | $1.86B | $1.48B | $1.42B | $1.40B | $1.29B | $1.21B |
Cash Flow
| Line item | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $450.76M | $115.85M | $164.84M | $66.70M | $66.70M | $239.19M |
| Investing Cash Flow | $678.94M | ($19.49M) | ($128.43M) | ($244.34M) | ($244.34M) | ($193.19M) |
| Financing Cash Flow | $13.14M | ($43.41M) | ($162.84M) | $233.12M | $233.12M | ($185.87M) |
| CapEx | $75.48M | $60.40M | $68.28M | $57.23M | $60.88M | $71.58M |
| Free Cash Flow | $375.28M | $55.44M | $96.57M | $9.47M | $5.82M | $167.60M |
Ratios
| Metric | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | 3.1% | 5.3% | 6.2% | 6.0% |
| Operating margin | - | - | 0.6% | 2.3% | 3.0% | 1.5% |
| EBITDA margin | - | - | 2.4% | 4.3% | 5.2% | 3.8% |
| Net margin | - | - | 0.3% | 1.9% | 1.6% | 0.7% |
| Free cash flow margin | - | - | 1.3% | 0.2% | 0.1% | 3.6% |
| FCF / Net income | 0.98 | 0.99 | 3.99 | 0.09 | 0.07 | 5.34 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | -13.2% | 30.8% | 44.0% | 18.5% | 47.2% | 57.4% |
| Return on assets | 11.4% | 1.8% | 0.8% | 3.7% | 3.2% | 1.5% |
| Return on equity | 20.4% | 4.0% | 1.9% | 8.6% | 7.1% | 2.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.92 | 1.84 | 1.72 | 1.66 | 1.21 | 1.52 |
| Quick ratio | 2.86 | 1.79 | 1.68 | 1.62 | 1.15 | 1.45 |
| Cash ratio | 1.55 | 0.36 | 0.30 | 0.45 | 0.28 | 0.16 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -1.3x | 2.2x | 1.2x | 5.2x | 14.3x | 10.8x |
| Equity multiplier | 1.80 | 2.21 | 2.32 | 2.32 | 2.22 | 1.94 |
| Liabilities / Assets | 0.43 | 0.55 | 0.57 | 0.57 | 0.55 | 0.48 |
| Efficiency | ||||||
| Asset turnover | - | - | 2.46 | 1.97 | 1.98 | 2.22 |
| Inventory turnover | 50.32 | 42.23 | 44.56 | - | - | - |
| Days sales outstanding | - | - | 38d | 41d | 46d | 34d |
| Days inventory outstanding | 7d | 9d | 8d | - | - | - |
| Days payable outstanding | 23d | 17d | 14d | - | - | - |
| Cash conversion cycle | - | - | 31d | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | 25.3% | 20.7% | 5.2% | 22.3% |
| Revenue CAGR (3y) | - | - | 16.7% | 15.8% | 10.9% | 12.8% |
| Revenue CAGR (5y) | - | - | 15.6% | 12.7% | 11.6% | 11.9% |
| Gross profit growth (YoY) | -43.0% | 10.8% | -26.7% | 3.0% | 9.5% | 3.3% |
| Operating income growth (YoY) | - | 87.1% | -68.1% | -7.1% | 104.6% | -39.7% |
| Net income growth (YoY) | 583.9% | 131.2% | -78.1% | 41.5% | 147.9% | -79.2% |
| EPS growth (YoY) | 557.0% | 135.1% | -78.5% | 40.1% | 166.1% | -58.3% |
| EPS CAGR (3y) | 49.2% | -10.9% | -7.1% | 15.9% | -10.8% | -39.3% |
| EPS CAGR (5y) | 65.4% | -4.7% | -26.5% | -3.6% | -5.0% | -10.9% |
| FCF growth (YoY) | 576.9% | -42.6% | 920.1% | 62.7% | -96.5% | 12.7% |
| FCF CAGR (5y) | 17.5% | -17.9% | -4.0% | -39.0% | -53.0% | -6.3% |
| Book value growth (YoY) | 33.8% | 8.8% | 0.7% | 16.1% | 3.1% | -5.9% |
Stability scores
Piotroski F-score
FY 2020 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Services-Hospitals
Comparing MAGELLAN HEALTH INC against the 3 most active filers in the same SIC group.